Astrazeneca ADR Stock
Price
Target price
€67.00
€67.00
1.540%
1.0
1.540%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
Astrazeneca ADR Stock
Astrazeneca ADR gained 1.540% today.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Astrazeneca ADR stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Astrazeneca ADR in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Astrazeneca ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Astrazeneca ADR | 1.540% | 0.775% | 6.557% | -13.907% | 1.563% | 0.000% | 34.855% |
| GSK plc ADR | 2.440% | 1.235% | -3.529% | -11.351% | 0.000% | -6.818% | -26.704% |
| Bayer AG ADR | -0.790% | -4.545% | -5.970% | 1.613% | 27.016% | -50.394% | -55.944% |
| Novo Nordisk A/S ADR | 2.230% | 4.534% | -27.712% | -64.160% | -48.983% | -59.381% | -25.175% |
News
Why AstraZeneca Stock Was Topping the Market on Tuesday
AstraZeneca (NASDAQ: AZN) reported an estimates-busting quarter Tuesday morning, and a satisfied market rewarded the company for it. At market close the sturdy pharmaceutical stock had risen by
Why AstraZeneca Stock Got Thumped on Thursday
AstraZeneca (NASDAQ: AZN) might soon be on the hook for an eventual 11-figure payout, and investors weren't all that comfortable with this. A Bloomberg article published Thursday morning said that
Why AstraZeneca Stock Topped the Market on Tuesday
Trading in AstraZeneca's (NASDAQ: AZN) American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a U.S. exchange. Investors clearly